Matt Miksic
Stock Analyst at Barclays
(3.92)
# 586
Out of 5,067 analysts
306
Total ratings
59.83%
Success rate
6.11%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDT Medtronic | Maintains: Overweight | $109 → $111 | $103.20 | +7.56% | 22 | Nov 20, 2025 | |
| OBIO Orchestra BioMed Holdings | Maintains: Overweight | $12 → $11 | $4.84 | +127.27% | 3 | Nov 12, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $51 → $55 | $21.47 | +156.17% | 8 | Nov 10, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $106 → $114 | $87.95 | +29.62% | 16 | Nov 10, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $301 → $316 | $337.53 | -6.38% | 11 | Nov 7, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Underweight | $105 → $104 | $93.52 | +11.21% | 9 | Nov 6, 2025 | |
| SENS Senseonics Holdings | Maintains: Overweight | $1.5 → $31 | $5.48 | +465.69% | 2 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Equal-Weight | $98 → $80 | $62.21 | +28.60% | 8 | Nov 3, 2025 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $22 → $23 | $20.63 | +11.49% | 4 | Nov 3, 2025 | |
| EW Edwards Lifesciences | Maintains: Overweight | $95 → $99 | $84.71 | +16.87% | 30 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $15.45 | +10.03% | 6 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $443 → $453 | $370.22 | +22.36% | 24 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $159 → $162 | $127.19 | +27.37% | 30 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $86 | $78.24 | +9.92% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $85 | $76.01 | +11.83% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $86 | $76.25 | +12.79% | 10 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $133 → $136 | $98.04 | +38.72% | 19 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3.5 | $1.28 | +173.44% | 1 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $55 → $58 | $60.46 | -4.07% | 8 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $36 | $18.18 | +98.02% | 22 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $21 | $13.82 | +51.95% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $165 → $176 | $206.05 | -14.58% | 13 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $241 | $190.96 | +26.20% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $684 → $635 | $568.48 | +11.70% | 7 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $3.73 | +490.60% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $74.46 | +34.30% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $143.63 | +191.03% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $16.78 | +66.87% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $10.73 | +524.42% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $480 | $2.59 | +18,432.82% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $12.48 | +597.39% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $5.39 | +363.82% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $6.78 | +32.74% | 1 | Dec 12, 2016 |
Medtronic
Nov 20, 2025
Maintains: Overweight
Price Target: $109 → $111
Current: $103.20
Upside: +7.56%
Orchestra BioMed Holdings
Nov 12, 2025
Maintains: Overweight
Price Target: $12 → $11
Current: $4.84
Upside: +127.27%
Tandem Diabetes Care
Nov 10, 2025
Maintains: Overweight
Price Target: $51 → $55
Current: $21.47
Upside: +156.17%
Globus Medical
Nov 10, 2025
Maintains: Overweight
Price Target: $106 → $114
Current: $87.95
Upside: +29.62%
Insulet
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $301 → $316
Current: $337.53
Upside: -6.38%
Zimmer Biomet Holdings
Nov 6, 2025
Maintains: Underweight
Price Target: $105 → $104
Current: $93.52
Upside: +11.21%
Senseonics Holdings
Nov 5, 2025
Maintains: Overweight
Price Target: $1.5 → $31
Current: $5.48
Upside: +465.69%
DexCom
Nov 3, 2025
Maintains: Equal-Weight
Price Target: $98 → $80
Current: $62.21
Upside: +28.60%
Alphatec Holdings
Nov 3, 2025
Maintains: Overweight
Price Target: $22 → $23
Current: $20.63
Upside: +11.49%
Edwards Lifesciences
Oct 31, 2025
Maintains: Overweight
Price Target: $95 → $99
Current: $84.71
Upside: +16.87%
Oct 31, 2025
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $15.45
Upside: +10.03%
Oct 22, 2025
Maintains: Overweight
Price Target: $443 → $453
Current: $370.22
Upside: +22.36%
Oct 17, 2025
Maintains: Overweight
Price Target: $159 → $162
Current: $127.19
Upside: +27.37%
Oct 13, 2025
Initiates: Equal-Weight
Price Target: $86
Current: $78.24
Upside: +9.92%
Oct 13, 2025
Initiates: Overweight
Price Target: $85
Current: $76.01
Upside: +11.83%
Oct 13, 2025
Initiates: Equal-Weight
Price Target: $86
Current: $76.25
Upside: +12.79%
Oct 2, 2025
Maintains: Overweight
Price Target: $133 → $136
Current: $98.04
Upside: +38.72%
Aug 27, 2025
Initiates: Overweight
Price Target: $3.5
Current: $1.28
Upside: +173.44%
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $55 → $58
Current: $60.46
Upside: -4.07%
Aug 4, 2025
Maintains: Overweight
Price Target: $41 → $36
Current: $18.18
Upside: +98.02%
Jul 30, 2025
Maintains: Overweight
Price Target: $24 → $21
Current: $13.82
Upside: +51.95%
Jul 17, 2025
Maintains: Equal-Weight
Price Target: $165 → $176
Current: $206.05
Upside: -14.58%
Jun 3, 2025
Maintains: Overweight
Price Target: $261 → $241
Current: $190.96
Upside: +26.20%
Apr 24, 2025
Maintains: Overweight
Price Target: $684 → $635
Current: $568.48
Upside: +11.70%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $3.73
Upside: +490.60%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $74.46
Upside: +34.30%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $143.63
Upside: +191.03%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $16.78
Upside: +66.87%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $10.73
Upside: +524.42%
Jan 7, 2022
Initiates: Outperform
Price Target: $480
Current: $2.59
Upside: +18,432.82%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $12.48
Upside: +597.39%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $5.39
Upside: +363.82%
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $6.78
Upside: +32.74%